Replimune, a cancer therapy developer, has announced the layoff of 63 employees at its Woburn facility following the FDA’s decision to stall approval of its RP1 cancer treatment. This development has significant implications for the local biotech community, which has experienced growth in recent years. The company will be scaling back its U.S. manufacturing operations and reassessing its development plans. Replimune is expected to provide further updates on its regulatory strategy in the coming months, emphasizing the ongoing challenges faced by biotech firms in the drug approval process.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://nationaltoday.com/us/ma/cambridge/news/2026/04/15/biotech-firm-cuts-63-jobs-in-woburn-after-fda-setback/
